Safety and efficacy characteristics of oral drugs in patients with premature ejaculation: a Bayesian network meta-analysis of randomized controlled trials

Abstract

Although previous studies have investigated the safety and efficacy characteristics of oral drugs in patients with premature ejaculation (PE), the available results remained inconsistent. Hence, this article was conducted to comprehensively compare the effectiveness of oral drugs and several relevant complications in patients with PE. Relevant researches were comprehensively searching from the databases PubMed, EMBASE, and Web of Science, up to May 1st, 2018. The pooled standard mean difference (SMD) or odds ratios (ORs) with 95% Credible interval (CrI) was respectively utilized to evaluate the safety and efficacy of oral drugs in PE. A total of 25 relevant research were ultimately included in this network meta-analysis. PE oral drugs mainly included serotonin reuptake inhibitors (SSRIs) and phosphodiesterase type 5 inhibitors (PDE5i). Our results successfully shed light on the efficacy differences of oral drugs for the treatment of PE. The cumulative rank probability of IELT at 4–6 weeks from best to worst was SSRIs + PDE5i, PDE5i, and other SSRIs alone. In addition, this meta-analysis also showed fluoxetine 20 mg, dapoxetine 60 mg, PDE5i, and SSRIs + PDE5i had a higher, whereas other SSRIs alone had a relatively lower incidence rate of clinically relevant complications. In summary, our results showed that the usage of PDE5i only or in combination with SSRIs might be stronger than SSRIs alone in the efficacy of PE oral drugs. Nevertheless, it also has a problem about the side effects of PDE5i including gastrointestinal or central nervous systems complications, which prevents it as the first-line treatment drug. Despite the development of some promising new therapeutic options, SSRIs remained as the first line of therapeutic PE oral drug through a synthetical consideration at present.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. 1.

    Puppo V, Sharif H. Premature ejaculation is not a disease. Int J Urol. 2017;24:641.

    Article  Google Scholar 

  2. 2.

    Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, et al. Premature ejaculation: results from a five-country European observational study. Eur Urol. 2008;53:1048–57.

    Article  Google Scholar 

  3. 3.

    McMahon CG, Althof S, Waldinger MD, Porst H, Dean J, Sharlip I, et al. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine ad hoc committee for the definition of premature ejaculation. BJU Int. 2008;102:338–50.

    Article  Google Scholar 

  4. 4.

    Richardson D, Goldmeier D, Green J, Lamba H, Harris JR. Recommendations for the management of premature ejaculation: BASHH special interest group for sexual dysfunction. Int J STD AIDS. 2006;17:1–6.

    Article  Google Scholar 

  5. 5.

    Jannini EA, Ciocca G, Limoncin E, Mollaioli D, Di Sante S, Gianfrilli D, et al. Premature ejaculation: old story, new insights. Fertil Steril. 2015;104:1061–73.

    Article  Google Scholar 

  6. 6.

    Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine ad hoc committee for the definition of premature ejaculation. J Sex Med. 2014;11:1423–41.

    Article  Google Scholar 

  7. 7.

    Polat EC, Ozbek E, Otunctemur A, Ozcan L, Simsek A. Combination therapy with selective serotonin reuptake inhibitors and phosphodiesterase-5 inhibitors in the treatment of premature ejaculation. Andrologia. 2015;47:487–92.

    CAS  Article  Google Scholar 

  8. 8.

    Eassa BI, El-Shazly MA. Safety and efficacy of tramadol hydrochloride on treatment of premature ejaculation. Asian J Androl. 2013;15:138–42.

    CAS  Article  Google Scholar 

  9. 9.

    McMahon CG. Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies--part II--study design, outcome measures, data analysis, and reporting. J Sex Med. 2008;5:1817–33.

    Article  Google Scholar 

  10. 10.

    Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy. J Sex Med. 2008;5:492–9.

    Article  Google Scholar 

  11. 11.

    Rajkumar RP, Kumaran AK. Depression and anxiety in men with sexual dysfunction: a retrospective study. Compr Psychiatry. 2015;60:114–8.

    Article  Google Scholar 

  12. 12.

    Mourikis I, Antoniou M, Matsouka E, Vousoura E, Tzavara C, Ekizoglou C, et al. Anxiety and depression among Greek men with primary erectile dysfunction and premature ejaculation. Ann Gen Psychiatry. 2015;14:34.

    Article  Google Scholar 

  13. 13.

    Abu EM, Abdelhamed A. Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: a randomised placebo-controlled clinical trial. Andrologia. 2018;50.

  14. 14.

    Propadalo I, Tranfic M, Vuka I, Barcot O, Pericic TP and Puljak L. In Cochrane reviews, risk of bias assessments for allocation concealment were frequently not in line with Cochrane's Handbook guidance. J clin epidemiol. 2019;10–17.

    Article  Google Scholar 

  15. 15.

    Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    CAS  Article  Google Scholar 

  16. 16.

    Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002;21:2313–24.

    Article  Google Scholar 

  17. 17.

    Shim SR, Kim SJ, Lee J and Rucker G. Network Meta-analysis: Application and Practice using R software. Epidemiol Health. 2019:e2019013.

    Article  Google Scholar 

  18. 18.

    Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ. 2013;347:f6008.

    Article  Google Scholar 

  19. 19.

    Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. Stat Sci. 1992;7:457–72.

    Article  Google Scholar 

  20. 20.

    Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29:932–44.

    CAS  Article  Google Scholar 

  21. 21.

    Sahin S, Bicer M, Yenice MG, Seker KG, Yavuzsan AH, Tugcu V. A prospective randomized controlled study to compare acupuncture and dapoxetine for the treatment of premature ejaculation. Urol Int. 2016;97:104–11.

    CAS  Article  Google Scholar 

  22. 22.

    Chen XY, Qu YW, Wang SG. Efficacy and safety of dapoxetine in the treatment of premature ejaculation. Zhonghua Nan Ke Xue. 2016;22:411–4.

    PubMed  PubMed Central  Google Scholar 

  23. 23.

    Yang L, Luo L, Chen XF, Fan JH, Liu RM, Wang XN, et al. Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation. Zhonghua Nan Ke Xue. 2015;21:892–5.

    PubMed  PubMed Central  Google Scholar 

  24. 24.

    Kirecci SL, Simsek A, Gurbuz ZG, Mimaroglu S, Yuksel A, Vural P, et al. Relationship between plasma melatonin levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation. Int J Urol. 2014;21:917–20.

    CAS  Article  Google Scholar 

  25. 25.

    Kirecci SL, Simsek A, Yuksel A, Gurdal H, Gurbuz ZG, Usanmaz S. Relevance of seminal plasma nitric oxide levels and the efficacy of SSRI treatment on lifelong premature ejaculation. Andrologia. 2014;46:1169–75.

    CAS  Article  Google Scholar 

  26. 26.

    Ozcan L, Polat EC, Otunctemur A, Ozbek E. Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation. Int Urol Nephrol. 2015;47:283–7.

    CAS  Article  Google Scholar 

  27. 27.

    Otunctemur A, Ozbek E, Kirecci SL, Ozcan L, Dursun M, Cekmen M, et al. Relevance of serum nitric oxide levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation: decreased nitric oxide is associated with premature ejaculation. Andrologia. 2014;46:951–5.

    CAS  Article  Google Scholar 

  28. 28.

    Gameel TA, Tawfik AM, Abou-Farha MO, Bastawisy MG, El-Bendary MA, El-Gamasy A. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab J Urol. 2013;11:392–7.

    Article  Google Scholar 

  29. 29.

    Lee WK, Lee SH, Cho ST, Lee YS, Oh CY, Yoo C, et al. Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. J Sex Med. 2013;10:2832–41.

    CAS  Article  Google Scholar 

  30. 30.

    Gong ZY, Tang TL, Cui S, Wang JZ, Deng XZ. Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue. 2011;17:923–5.

    PubMed  PubMed Central  Google Scholar 

  31. 31.

    McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med. 2011;8:524–39.

    Article  Google Scholar 

  32. 32.

    McMahon C, Kim SW, Park NC, Chang CP, Rivas D, Tesfaye F, et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med. 2010;7(1 Pt 1):256–68.

    CAS  Article  Google Scholar 

  33. 33.

    Vahid F, Firoozeh R, Ghasem MM, Davood A. On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Medica Irani. 2009;47:353–5.

  34. 34.

    Mathers MJ, Klotz T, Roth S, Lummen G, Sommer F. Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. Andrologia. 2009;41:169–75.

    CAS  Article  Google Scholar 

  35. 35.

    Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol. 2009;55:957–67.

    CAS  Article  Google Scholar 

  36. 36.

    Mattos RM, Marmo LA, Srougi M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int. 2008;80:162–5.

    CAS  Article  Google Scholar 

  37. 37.

    Arafa M, Shamloul R. A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire. Ther Clin Risk Manag. 2007;3:527–31.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Athanasios Z, Polyanthi P, George K. The efficacy of duloxetine in the treatment of premature ejaculation. Int Urol Nephrol. 2007;39:115–8.

    CAS  Article  Google Scholar 

  39. 39.

    Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006;368:929–37.

    CAS  Article  Google Scholar 

  40. 40.

    Safarinejad MR. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol. 2006;29:243–52.

    CAS  Article  Google Scholar 

  41. 41.

    Hosseini MM, Yarmohammadi H. Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. Urol Int. 2007;79:28–32.

    CAS  Article  Google Scholar 

  42. 42.

    McMahon CG, Stuckey BG, Andersen M, Purvis K, Koppiker N, Haughie S, et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med. 2005;2:368–75.

    CAS  Article  Google Scholar 

  43. 43.

    Atmaca M, Kuloglu M, Tezcan E, Semercioz A. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002;14:502–5.

    CAS  Article  Google Scholar 

  44. 44.

    Althof SE, Abdo CH, Dean J, Hackett G, McCabe M, McMahon CG, et al. International Society for Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med. 2010;7:2947–69.

    Article  Google Scholar 

  45. 45.

    Aversa A, Pili M, Francomano D, Bruzziches R, Spera E, La Pera G, et al. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int J Impot Res. 2009;21:221–7.

    CAS  Article  Google Scholar 

  46. 46.

    Jannini EA, McMahon C, Chen J, Aversa A, Perelman M. The controversial role of phosphodiesterase type 5 inhibitors in the treatment of premature ejaculation. J Sex Med. 2011;8:2135–43.

    Article  Google Scholar 

  47. 47.

    Salonia A, Maga T, Colombo R, Scattoni V, Briganti A, Cestari A, et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol. 2002;168:2486–9.

    CAS  Article  Google Scholar 

  48. 48.

    Asimakopoulos AD, Miano R, Finazzi Agrò E, Vespasiani G, Spera E. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? a systematic review and meta‐analysis. J Sex Med. 2012;9:2404–16.

    CAS  Article  Google Scholar 

  49. 49.

    McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int. 2006;98:259–72.

    CAS  Article  Google Scholar 

  50. 50.

    Althof SE, McMahon CG, Waldinger MD, Serefoglu EC, Shindel AW, Adaikan PG, et al. An update of the International Society of Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation (PE). Sex Med. 2014;2:60–90.

    Article  Google Scholar 

  51. 51.

    Sun Y, Luo D, Yang L, Tang C, Yang T, Hu X, et al. Efficacy of phosphodiesterase-5 inhibitor in men with premature ejaculation: a new systematic review and meta-analysis. Urology. 2015;86:947–54.

    Article  Google Scholar 

  52. 52.

    Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology. 2006;31:473–92.

    CAS  Article  Google Scholar 

  53. 53.

    Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.

    Article  Google Scholar 

  54. 54.

    Yafi FA, Sharlip ID, Becher EF. Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Sex Med Rev. 2018;6:242–52

    Article  Google Scholar 

  55. 55.

    Sun Y, Yang L, Bao Y, Liu Z, Liu L, Wei Q. Efficacy of PDE5is and SSRIs in men with premature ejaculation: a new systematic review and five meta-analyses. World J Urol. 2017;35:1817–31.

    CAS  Article  Google Scholar 

  56. 56.

    Nakaoka H, Inoue I. Meta-analysis of genetic association studies: methodologies, between-study heterogeneity and winner’s curse. J Hum Genet. 2009;54:615–23.

    Article  Google Scholar 

Download references

Author’s contribution

WZ, NHS, and ZJW: protocol/project development; JDX, CQ, and WW: data collection or management; KZ, RL, LZ, and XHM: data analysis; ZQQ, YW, and JDZ: manuscript writing/editing.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Ninghong Song or Zengjun Wang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Qin, Z., Wang, Y., Zhu, J. et al. Safety and efficacy characteristics of oral drugs in patients with premature ejaculation: a Bayesian network meta-analysis of randomized controlled trials. Int J Impot Res 31, 356–368 (2019). https://doi.org/10.1038/s41443-019-0146-7

Download citation

Further reading

Search

Quick links